Articles On Rhythm Biosciences (ASX:RHY)

The Rhythm Biosciences Ltd (ASX: RHY) share price has continued its positive run on Tuesday. At one stage, the medical device company’s shares were up 15% to a record high of $1.30. This is almost 1,000% higher than this time last year, ma...

While most ASX companies already have products sold in the market and have built sales traction, there are also companies that are still preparing for market launch. Here I’ve listed down three ASX small cap companies that are preparing to...

The Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month period. From the beginning of November alone, the share price has soared over 355%.  For the past few weeks, we’ve been watching Rhythm Biosc...

The Rhythm Biosciences Ltd (ASX: RHY) share price is climbing today after the company was granted a United States patent for ColoSTAT. At the time of writing, the Rhythm share price is up 5% to 84 cents. Rhythm develops and commercialises...

The Rhythm Biosciences Ltd (ASX: RHY) share price was an outstanding performer on Friday. At one stage, the medical device company’s shares were up 28% to a record high of 95 cents. The Rhythm Biosciences share price eventually ended the d...

Rhythm Biosciences (ASX: RHY) has appointed French company Biotem as the global manufacturer of its ColoSTAT test-kit.

Small cap ASX shares live in a world of their own. Some strike gold, some don’t. Here are some across the mining and healthcare sectors that managed to deliver significant shareholder value in November.  Best performing small cap ASX share...

Rhythm Biosciences (ASX:RHY) shares climbed again today after achieving its latest milestone – completing a prototype test kit. The company is ... Read More The post Rhythm Biosciences proves its colorectal cancer test is for real; shares u...

A few ‘Karens’ aside, Australians are largely willing to take the basic steps to avoid the coronavirus – but they ... Read More The post Dr Boreham’s Crucible: Rhythm Biosciences’ share price is passing the sniff test again appeared first o...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The health sector made a bit of progress over the last fortnight, with 64 small-cap life sciences gaining ground and just 52 losing it. Another 15 companies were flat....

A quick wrap of the ASX’s key winners and losers on Monday, September 14. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   WINNERS Code Na...

A quick wrap of the ASX’s key winners and losers on Friday, August 14. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 902 stocks rose, 501 declined and 6...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The pundit...

A quick wrap of the ASX’s key winners and losers on Thursday, July 23. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 798 stocks rose, 500 de...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

A quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 571 stocks rose, 750 declined and 786...

Allied health group Advent Health is preparing to join the ranks of the ASX by way of a reverse takeover next month with a plan to improve efficiencies and boost profitability of its founding practices. The move entails shell company Mill...

Rhythm Biosciences (ASX:RHY) has announced the appointment of Eduardo Vom as a new non-executive director.

While the ASX falters, one small-cap is booming. The share price of Rhythm Biosciences Ltd [ASX:RHY] is up 127% at time of writing. Surging on the back of an update in regards to the company's cancer screening tech. The post Rhythm Bioscien...

Australian medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed the antibodies in a lead biomarker of a blood test for the accurate and early detection of colorectal cancer have been successfully validated, stabilised and...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Pharmaceutical company Race Oncology (ASX: RAC) has come out of a trading halt this morning to announce $1.8 million new equity funding via a strategic placement of 6 million shares. The $0.30 per share issue price represents a 9% discount...

Gastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just because they may have you running to the loo every five minutes. The field covers many diseases like Irritable Bowel Syndrome (IBS), Crohn’s...

Yesterday, Stockhead reviewed the small caps that are devising treatments to fight cancer. There are also a handful of small caps that are seeking to help with diagnostics. In other words these small caps are either seeking to identify the...

Every two weeks, Stockhead takes a look at the small cap companies that are releasing shares that have been locked away in escrow. Escrow refers to shares that are held by early investors or directors restrained from selling for a year or t...

Rhythm Biosciences (ASX: RHY) has announced the appointment of a new director and chair. The company said Otto Buttula will succeed Shane Tanner. Mr Buttula is a well-known sector...

There’s an old saying — ‘an apple a day keeps the doctor away’. But these days, its biotechs — not apples — that are working hard to keep patients out of a congested medical system. Rhythm Biosciences (ASX: RHY) main asset is Colostat – a b...

Trading Places is Stockhead’s weekly recap of substantial holder movements focusing on fund managers. Substantial shareholders are shareholders holding 5 per cent or more of a company’s shares and these can be directors, individual investor...

Rhythm Biosciences (ASX:RHY) says recent testing has indicated new antibodies for the key lead biomarker used in its ColoSTAT test are able to successfully differentiate between cancer and healthy samples.

Rhythm Biosciences Limited (ASX:RHY) today announced that recent testing has indicated that the new antibodies for the key lead biomarker used in its ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the...

Medical diagnostics company Rhythm Biosciences Ltd (ASX:RHY) has continued to develop its global, low-cost, lifesaving blood test for the detection of colorectal cancer, ColoSTAT®, during the last quarter. Following 13 years of CSIRO resear...

Queenstown is known as the adventure capital of the world. It attracts over three million people per year to experience the world-class ski runs, zip-line riding, white water rafting, sky diving and is, of course, famous for manufacturing t...

Dimerix Limited (ASX: DXB) Clinical-stage biopharmaceutical company, Dimerix Limited (ASX: DXB) is engaged in developing new therapies for the unmet requirements of the medicine market all over the world. On 26 June 2019, Dimerix announced...

ColoSTAT has the potential to play an important role in reducing morbidity and mortality rates associated with colorectal cancer.

Rewardle Holdings Limited Social media company Rewardle Holdings Limited (ASX: RXH) connects more than 3.2 million members with nearly 5,000 local businesses across Australia. Strategic Partnership with Pepper Leaf Meal Kit Delivery Servic...

Monash Health will be the second clinical trial site with the company expecting to sign further hospitals to join the ColoSTAT trial in coming weeks.

Monash Health has become the second hospital to join the Rhythm Biosciences (ASX:RHY) prospective clinical trial of ColoSTAT - its blood test for the early detection of colorectal cancer.